CD19 and acute lymphoblastic leukemia: In a recent phase 1 trial reported by the University of Pennsylvania and Children’s Hospital of Pennsylvania (CHOP), 3 of 27 responders (11%) relapsed with B-ALL without detectable CD19 [10].